Abstract
A growing body of evidence suggests that low molecular weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS) including acute myocardial infarction. Several studies support an early invasive as compared to a conservative (non-invasive) approach utilizing percutaneous coronary intervention (PCI) in these patients. During coronary angiography and PCI systemic anticoagulation usually administering UFH should prevent thrombus formation at the catheter equipment and at the site of vessel injury. The widespread use of UFH as the anticoagulant of choice is explained by low costs, easy reversibility and accepted anticoagulant properties. However, the clinical support for the use of UFH in PCI is largely based on retrospective and observational data only. Compared to UFH, LMWH have distinct pharmacological advantages, including ease of administration and usually no need for monitoring. A major drawback of LMWH is the predominant renal clearance which may lead to unpredictable levels of anticoagulation in patients with impaired renal function. Since LMWH constitute an extremely heterogeneous group of drugs each LMWH should be recognized as an individual pharmaceutical compound. Consequently, pharmacodynamic and pharmacokinetic properties of one LMWH must not be extrapolated for other LMWH. A growing body of evidence supports the use of LMWH in ACS, with or without GPIIb / IIIa receptor antagonists, thrombolysis, or PCI. Although in patients undergoing PCI, LMWH have yet not been shown to be superior to UFH they can safely be administered.
Keywords: Low-Molecular Weight Heparins, LMWH, percutaneous coronary intervention (PCI), unfractionated heparin (UFH)
Current Pharmaceutical Design
Title: Low-Molecular Weight Heparins in Percutaneous Coronary Interventions: Current Concepts, Problems, and Perspectives
Volume: 10 Issue: 4
Author(s): Graf J. and Janssens U.
Affiliation:
Keywords: Low-Molecular Weight Heparins, LMWH, percutaneous coronary intervention (PCI), unfractionated heparin (UFH)
Abstract: A growing body of evidence suggests that low molecular weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS) including acute myocardial infarction. Several studies support an early invasive as compared to a conservative (non-invasive) approach utilizing percutaneous coronary intervention (PCI) in these patients. During coronary angiography and PCI systemic anticoagulation usually administering UFH should prevent thrombus formation at the catheter equipment and at the site of vessel injury. The widespread use of UFH as the anticoagulant of choice is explained by low costs, easy reversibility and accepted anticoagulant properties. However, the clinical support for the use of UFH in PCI is largely based on retrospective and observational data only. Compared to UFH, LMWH have distinct pharmacological advantages, including ease of administration and usually no need for monitoring. A major drawback of LMWH is the predominant renal clearance which may lead to unpredictable levels of anticoagulation in patients with impaired renal function. Since LMWH constitute an extremely heterogeneous group of drugs each LMWH should be recognized as an individual pharmaceutical compound. Consequently, pharmacodynamic and pharmacokinetic properties of one LMWH must not be extrapolated for other LMWH. A growing body of evidence supports the use of LMWH in ACS, with or without GPIIb / IIIa receptor antagonists, thrombolysis, or PCI. Although in patients undergoing PCI, LMWH have yet not been shown to be superior to UFH they can safely be administered.
Export Options
About this article
Cite this article as:
Graf J. and Janssens U. , Low-Molecular Weight Heparins in Percutaneous Coronary Interventions: Current Concepts, Problems, and Perspectives, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453342
DOI https://dx.doi.org/10.2174/1381612043453342 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Current Signal Transduction Therapy Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Mechanosensitive Channels: Therapeutic Targets in the Myocardium?
Current Pharmaceutical Design The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Pro-angiogenic Molecules for Therapeutic Angiogenesis
Current Medicinal Chemistry Nanofibers Based Tissue Engineering and Drug Delivery Approaches for Myocardial Regeneration
Current Pharmaceutical Design Current Status of Carotid Stenting
Current Vascular Pharmacology Adrenomedullin in Cardiovascular Disease: A Useful Biomarker, its Pathological Roles and Therapeutic Application
Current Protein & Peptide Science Shedding Light on the Pathophysiology of Preeclampsia-Syndrome in the Era of Cardio-Obstetrics: Role of Inflammation and Endothelial Dysfunction
Current Hypertension Reviews NOAC in Acute Coronary Syndrome and AF?
Cardiovascular & Hematological Disorders-Drug Targets Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design Multitarget Antithrombotic Drugs
Current Topics in Medicinal Chemistry Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology